Skip to NavigationSkip to content

AstraZeneca's cediranib combo misses main goal in platinum-sensitive relapsed ovarian cancer

Published on 13/03/20 at 12:46pm

Newly revealed Phase 3 data has shown that AstraZeneca’s oral vascular endothelial growth factor receptor (VEGFR) inhibitor cediranib, when combined with Lynparza (olaparib), failed to meet its main goal in clinical trials.

In the US National Cancer Institute-sponsored study, the combo failed to meet its primary endpoint of statistically significant improvement in progression-free survival (PFS) in the intent-to-treat population compared to platinum-based chemotherapy in platinum-sensitive relapsed ovarian cancer.

Despite this, the combo’s safety profile was found to be in line with previous data.

“Despite these disappointing results, we remain committed to expanding on the benefits already demonstrated with Lynparza for patients with advanced ovarian cancer,” said José Baselga, Executive Vice President, Oncology R&D. “We will work closely with NRG Oncology and the NCI to review the full results to inform our ongoing research.”

Ovarian cancer is the eighth most deadly cancer in the world for women. Cediranib fights the disease by inhibiting the expansion of tumours through blocking the growth of the blood vessels that sustain them.

Matt Fellows

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches